| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 12.49 | 32.5% |
| Total Income | 12.49 | 32.5% |
| Expenditure | 13.40 | 7.4% |
| PBT | -2.00 | 51.5% |
| Net Profit | -2.11 | 49.2% |
| OPM | -7.29% | 25.06pp |
| NPM | -16.88% | 27.13pp |
| EPS | -0.05 | 50.0% |
Apyx Medical Reports Q1 2026 Revenue of $12.5 Million, Up 32.4% YoY
07 May 2026 · 7 May, 4:38 pm
Summary
Apyx Medical Corporation reported a strong first quarter in 2026, with total revenue increasing by 32.4% to $12.5 million. The growth was primarily driven by a 36.1% increase in Surgical Aesthetics revenue, fueled by AYON sales and international Renuvion demand. The company's net loss attributable to stockholders decreased significantly to $2.1 million. Apyx Medical has raised its full-year revenue guidance for 2026 to $59.0 million to $60.0 million, reflecting confidence in the business's performance.
Key Highlights
- 1
Apyx Medical Corporation reported total revenue of $12.5 million in the first quarter of 2026, a 32.4% increase compared to the same period last year.
- 2
Surgical Aesthetics revenue increased by 36.1% to $10.7 million in the first quarter of 2026, driven by domestic sales of AYON and international sales of Renuvion generators.
- 3
OEM revenue increased by 13.8% to $1.8 million in the first quarter of 2026.
- 4
Net loss attributable to stockholders decreased to $2.1 million in the first quarter of 2026, compared to $4.2 million in the first quarter of 2025.
- 5
Adjusted EBITDA loss improved to $0.3 million for the first quarter of 2026, compared to an Adjusted EBITDA loss of $2.4 million for the first quarter of 2025.
- 6
The company raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million.
- 7
International sales exceeded expectations, particularly in South Korea following regulatory approval in December 2025.
Management Comments
Charlie Goodwin
Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide. During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026
Informational and educational content only. Not investment advice.